Newron Pharmaceuticals S.p.A. (SIX: NWRN, XETRA: NP5) announced today that its shareholders approved all motions on the agenda for the ordinary part of the Annual General Meeting (AGM) 2026, held on April 23. The approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, non-executive Board members. However, the motions on the agenda for the extraordinary part of the meeting were not put to a vote because the required quorum was not reached.
Chris Martin, Chairman of the Board of Directors of Newron, expressed gratitude to shareholders for their trust and welcomed the newly elected Board members, anticipating their valuable contributions. He also thanked Patrick Langlois and Luca Benatti, who stepped down after long-standing service, for their support of the company.
Newron, a biopharmaceutical company focused on developing novel therapies for central and peripheral nervous system diseases, is headquartered in Bresso near Milan, Italy. The company has a strong track record in advancing neuroscience treatments from discovery to market. Its lead compound, evenamide, is a first-in-class glutamate modulator with potential as the first add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding schizophrenia patients. Evenamide is currently in the global pivotal ENIGMA-TRS Phase III development program. Clinical trial results have shown benefits in TRS and poorly responding patients, with significant improvements across key efficacy measures increasing over time, along with a favorable safety profile uncommon for available antipsychotic medications.
Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. The company's first marketed product, Xadago®/safinamide, has received marketing authorization for Parkinson's disease treatment in multiple regions, including the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The product is commercialized by Newron's partner Zambon, with Supernus Pharmaceuticals holding U.S. marketing rights and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories.
For more information about Newron, visit www.newron.com. The original press release is available at www.newmediawire.com.
